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Abstract— Inhibitors of melanin formation are sought after for a range of applications. Boronophenylalanine is known to inhibit
melanogenesis via boronic acid-catechol interactions. A spectroscopic assay was developed to study the polymerization of L-dopa to
synthetic melanin in the presence of para-substituted aryl boronic acids. The best inhibition was observed for aryl boronic acids with
electron-withdrawing substituents. The IC50 values exhibit a correlation with the Hammett σp parameter (ρ = 0.97, r2 = 0.92).

The relationship between boronophenylalanine (BPA,
Fig. 1) and melanogenesis is a fascinating and relatively
unheralded chapter in bioorganic chemistry.1-4 Melanin
is produced in melanocytes, which are also the
precursor cells for malignant melanoma. The enzyme
tyrosinase5 carries out the initial steps of melanogenesis6 by catalyzing two successive oxidations of the
amino acid tyrosine: a hydroxylation of the phenol ring
to provide L-dopa followed oxidation to the quinone
form (dopaquinone). Tyrosinase activity and melanin
production typically increase in the initial stages of
malignant transformation. Beginning in 1980, Mishima
and co-workers investigated the 10B isotopomer of the
tyrosine/dopa mimic BPA as a candidate for boron
neutron capture therapy (BNCT) treatment of malignant
melanoma.1-4,7 As hypothesized, BPA accumulates in
melanocytes, yet the predominant target doesn’t appear
to be the enzyme tyrosinase. Instead, BPA binds
directly to melanogenesis intermediates via boronic
acid-catechol interactions (Fig. 1).2-4
Boronic acids are well known to form reversible
covalent adducts with neighboring hydroxyls in sugars814
and catechols.12-20 These interactions have been
widely explored for materials science17 and bioanalytical applications, including chromatography8 and
sensors for diols,21 carbohydrates,9-11 catecholamines,18,19 and multivalent catechols.20 Recently, green
tea has been suggested as a dietary modulator of the
boronic
acid-containing
proteasome
inhibitor
bortezomib, via the interaction of its boronic acid with
catechol-containing components of green tea.22

Figure 1. BPA, a mimic of tyrosine and L-dopa, has been found to form
reversible covalent adducts with late stage melanogenesis intermediates
including DHI, DHICA, and DHI/DHICA oligomers.

Mishima and co-workers identified the late stage
intermediates 5,6-dihydroxyindole (DHI) and 5,6dihydroxyindole-2-carboxylic acid (DHICA), as well as
DHI/DHICA oligomers as key binding partners of
BPA.2-4 DHI and DHICA are considered the primary
monomers of eumelanin, the black to brown pigment.6
In addition to reversible covalent bond formation, BPA
adducts can break down irreversibly to release borate,
which can form additional adducts.3,4 Covalent trapping
of BPA/borate concentrates 10B within the melanoma
cell, as desired for BNCT. Mishima and co-workers
performed BNCT clinical trials1-4,7 and also leveraged
their discovery by using BPA as a tool for studying the
melanogenesis pathway and treating hyperpigmentation
disorders.2-4

We have been inspired to revisit boronic acidmelanogenesis interactions as a tool for probing the
natural system and a modifier for generating ‘synthetic
melanin’ analogs. There is a growing interest in
exploiting the properties of melanins and related
synthetic analogs for non-biological applications.23-26
As materials applications are developed, precise control
over the rate of polymerization will be increasingly
desirable. To the extent that these polymerizations
mimic melanogenesis and/or utilize catechol-containing
intermediates, boronic acids could be effective
polymerization modulators. Along with 11B NMR and
in vivo studies, Mishima and co-workers had used a
synthetic polymerization assay with a visual readout to
observe inhibition by BPA and a few other boroncontaining
species.3
Among
their
findings,
phenylboronic acid and BPA inhibited polymerization
to a similar degree while tetraphenylborate was noninhibitory. We reasoned that a spectroscopic assay
might allow for finer discrimination among similar
boronic acids. We were particularly interested to see if
a Hammett correlation would emerge from the
inhibition of synthetic melanin polymerization by a
series of para-substituted aryl boronic acids.
We monitored the polymerization of L-dopa to synthetic
melanin initiated by the chemical oxidant sodium
periodate (NaIO4) by UV/Vis spectroscopy at 600 mm.
Absorbance at 600 nm is often taken as a proxy for light
scattering indicative of particulate matter. In this
polymerization, black, macroscopically particulate
material forms on the time scale of hours. Both
scattering and the broad absorbance of the melanin-like
material may contribute to OD600. We found that OD600
increases linearly during an extended phase of the
polymerization. Polymerizations were initiated by
mixing L-Dopa (4.0 mM) with NaIO4 (3.0 mM), in 50
mM sodium phosphate buffer pH 7.0 at room
temperature. Sodium periodate has been used by
Mishima3 and others27 to rapidly oxidize L-dopa,
initially to dopaquinone. The solution turns red quickly,
indicating the brightly colored eumelanin intermediate
dopachrome (εmax at 475 nm) is a predominant species
in solution at this stage. After 5 minutes at room
temperature, aliquots of the red L-Dopa/NaIO4 solution
are added to wells of a 96-well plate, containing the
same phosphate buffer and DMSO, with or without
boronic acids. We refer to the 2-fold dilution of the
initial mixture, for example, as [L-dopatotal] = 2 mM,
where L-dopatotal refers to L-dopa itself and all derived
polymerization intermediates. All wells have a final
volume of 300 µL including 15 µL DMSO (5%). The
96-well plate is placed in a microplate reader equipped
with an incubator/shaker (BioRad Microplate Plus) at
25 °C, and OD600 monitored every 30 seconds with 10
second shaking intervals.
After ~15 minutes, we
observe an increase in OD600 that is linear for at least an
hour for [L-dopatotal] = 2 mM. At lower [L-dopatotal]
there is a longer induction time to reach a linear

ΔOD600/min and within the linear phase ΔOD600/min
decreases with decreasing [L-dopa]total (Fig. 2). The
measured ΔOD600/min values correlate with differences
in solution darkening and ultimately visible particulate
matter as observed by eye.

Figure 2. Plot of OD600 for synthetic melanin polymerization 30-60 min
after placement in the microplate reader at 25 °C. Each well contains the
indicated concentration of L-dopatotal (prepared as described in the text),
50 mM sodium phosphate buffer, pH 7.0, and 5% DMSO. Average
values from three independent titrations shown, error bars represent one
standard deviation. Best fit lines shown in black.

With a fixed [L-dopatotal] value of 2 mM, increasing
concentrations of boronic acids increase the length of
the induction period and decrease ΔOD600/min in the
linear phase. Boronic acid concentrations were adjusted
such that all trials enter the linear phase prior to t = 30
min from placement in the microplate reader (25 °C).
OD600 readings from t = 30 min to t = 60 min were
graphed and ΔOD600/min determined. In all included
trials, slopes were linear (r2 ≥ 0.98).
Seven
concentrations per boronic acid were tested per titration,
as well as a L-dopatotal-only control. Independent
titrations were performed in triplicate. A series of ten
para-substituted aryl boronic acids with substituents
–OMe (methoxy), –CH3 (methyl), –H, –F, –Cl, –Br,
–Ac (acetyl), –CF3 (trifluoromethyl), –CN (cyano), and
–NO2 (nitro) were tested, as well as sodium borate.
Representative titrations for 4-cyanophenyl boronic acid
and 4-methoxyphenyl boronic acid are shown in
Figures 3A-B, respectively. The relative rate
(ΔOD600/min with boronic acid/ΔOD600/min without)
has an empirical linear correlation with log ([boronic
acid]) (r2 ≥ 0.98 for all boronic acids tested, seven
concentrations each, tested in triplicate). Representative
data is shown in Figure 3C. Using this empirically
determined relationship the point of 50% inhibition was
calculated. These IC50 values are presented in Table 1,
along with the percentage rate (100 x relative rate)
observed when [boronic acid] = [L-dopa]total = 2 mM.
It is apparent that the aryl boronic acids with electronwithdrawing substituents are more effective inhibitors
than those with electron-donating substituents. Indeed,
as shown in Figure 3D, there is a reasonable Hammett
correlation28,29 evident in the plot of –log (IC50/IC50,H)
vs. the Hammett σp parameter (r2 = 0.92), with a slope
(ρ) of 0.97.

Figure 3. Aryl boronic acid inhibition of synthetic melanin polymerization. A&B) Individual titrations of 4-cyanophenyl boronic acid (A) and 4-methoxyphenyl boronic acid (B). Plots of OD600 30-60 min after placement in the microplate reader at 25 °C. Each well contains 2 mM L-dopatotal (prepared as
described in the text), the indicated concentration of boronic acid, 50 mM sodium phosphate buffer, pH 7.0, and 5% DMSO. Best fit lines shown in black.
C) Plot of relative rate (ΔOD600/min with boronic acid/ΔOD600/min without) vs. log ([boronic acid]) and for representative para-substituted aryl boronic
acids (-OMe, -Cl, -CN). Three independent titrations each, error bars represent one standard deviation, best fit lines shown in black. D) Hammett
correlation between the empirical IC50 calculated from the best fit lines of plots such as shown in 3C for ten para-substituted aryl boronic acids.
Table 1. Boronic acid inhibition of synthetic melanin polymerization
X

B

OH
OH

σ pa

IC50b
(mM)

% Ratec
with 2 mM
Boronic Acid

X=
–OMe
–0.28
6.20 (±0.32)
66.1 (±2.7)
–CH3
–0.14
4.45 (±0.21)
62.8 (±2.0)
1.84 (±0.11)
–H
0
51.7 (±1.1)
1.84 (±0.11)
–F
0.15
49.7 (±2.1)
1.31 (±0.08)
–Cl
0.24
41.2 (±0.7)
1.03 (±0.08)
–Br
0.26
37.7 (±1.3)
0.69 (±0.04)
–Ac
0.47
30.5 (±1.5)
0.80 (±0.06)
–CF3
0.53
26.9 (±1.0)
0.59 (±0.04)
–CN
0.70
19.4 (±1.3)
0.55 (±0.05)
–NO2
0.81
21.5 (±1.3)
1.36 (±0.06)
Sodium Borate
44.3 (±1.3)
a
σp values from reference 29. bCalculated using the empirical linear
relationship between log ([boronic acid]) and relative rate (ΔOD600/min
with boronic acid/ΔOD600/min without). c% rate = 100 x relative rate.

Increased inhibitory potency for electron-withdrawing
substituents is consistent with general trends in boron
acid-diol binding interactions.8,10-15 Aryl boronic acids
with electron-withdrawing substituents have lower
pKa’s and generally have stronger interactions with
diols near neutral pH, although there are exceptions to
the latter point.12,13 Independent studies of the acidity
of aryl boronic acids under diverse experimental

conditions find ρ values of ~2.1.13,28,30 Compared to the
present results, this indicates that the observed
inhibition is less sensitive to the nature of the para
substituent than the acidity of these same compounds.
Wang and co-workers have shown that the relationship
between aryl boronic acid pKa’s and diol binding
constants is complicated.13 Optimal complex formation
depends on a pKa match between boronic acid and diol
relative to the pH, as well as other factors. Here, the
aryl boronic acids could be interacting with a range of
different, related species, including the DHI/DHICA
monomers and soluble oligomers, remaining earlier
intermediates including L-dopa itself, and/or with
catechol groups on the surface of nascent particles. In
each case the catechol group will have a somewhat
different pKa and steric environment. Thus, we suspect
that the Hammett correlation reflects boronic acidcatechol binding but further computational and
experimental work will be necessary to differentiate
between potential interactions.
We considered two other possibilities for the inhibitory
potency of the aryl boronic acids. Control experiments
with strong acid (HCl) and base (NaOH) ruled out the
significance of indirect, through-pH effects, as expected
for a buffered system. (However, once the buffer
capacity is overcome there is pH dependence to

ΔOD600/min, with slower rates at high [H+]). We also
considered the role of borate. Using 11B NMR,
Mishima and co-workers had observed irreversible
decomposition of BPA-DHI complexes to release
borate, on a time-scale of hours to days.4 For some of
the aryl boronic acids tested here, the reaction could be
accelerated such that it occurs to a significant extent
during the assay. Borate can cross-link catecholic
species which could have an uncertain effect on the
OD600.
Cross-linked aggregates might inhibit the
normal polymerization and/or be large enough to
increase scattering. In the event, sodium borate has a
net inhibitory effect on ΔOD600/min, with an IC50
similar to 4-chlorophenyl boronic acid (Table 1). Since
many of the aryl boronic acids had lower IC50’s, this
suggests that the production of borate, should it occur,
isn’t the dominant inhibitory factor.
In summary, we have found that aryl boronic acids and
sodium borate inhibit the polymerization of L-dopa to
synthetic melanin as measured by a simple
spectroscopic assay. Aryl boronic acids with electronwithdrawing substituents are more inhibitory than those
with electron-donating substituents, which we attribute
to formation of stronger boronic acid-catechol
complexes. In recent years there has been an explosion
in the number of commercially available aryl boronic
acids. This study suggests that they may be useful to
modify melanin-related polymerizations for materials
applications, in vitro models of melanin biochemistry,
and potentially in vivo pharmacological intervention, as
with BPA.1-4 Tyrosinase inhibitors5,31 are widely sought
after for cosmetic, therapeutic, and agricultural
applications; boronic acids might be alternatives to, or
act synergistically with, tyrosinase inhibitors. Finally, a
three-component version of the assay with added sugars
may be a useful reporter for carbohydrate analysis.
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